Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425711 · ClinicalTrials.gov registry record · NA
Study of Acamprosate in Driving Under the Influence (DUI) Court Participants
A NA study, sponsored by University of Oklahoma.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT00425711 is a NA study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 4 participants.
The verdict
NCT00425711, a NA study, was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
Acamprosate will be given to approximately 30 DUI Court participants for 3 months and outcomes will be monitored. The hypothesis is that acamprosate will be safe and well-tolerated and that subjects' craving and other symptoms related to addiction will improve over time.
Interventions
- DRUG Acamprosate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00425711
The ClinicalTrials.gov registry entry for NCT00425711 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acamprosate is the first listed.
NCT00425711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00425711 about?
NCT00425711 is a clinical study titled "Study of Acamprosate in Driving Under the Influence (DUI) Court Participants". Acamprosate will be given to approximately 30 DUI Court participants for 3 months and outcomes will be monitored. The hypothesis is that acamprosate will be safe and well-tolerated and that subjects' craving and other symptoms related to addiction will improve over time.
What is the current status of trial NCT00425711?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2007-02. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00425711?
The interventions under investigation include: Acamprosate (DRUG).
Who is sponsoring clinical trial NCT00425711?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.